Results 31 to 40 of about 60,411 (353)

EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease

Movement Disorders, 2019
Real‐life observational report of clinical efficacy of bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD).
H. Dafsari, P. Martínez-Martín, A. Rizos, M. Trost, M. G. dos Santos Ghilardi, P. Reddy, A. Sauerbier, J. Petry-Schmelzer, M. Kramberger, R. Borgemeester, M. Barbe, K. Ashkan, M. Silverdale, J. Evans, P. Odin, E. Fonoff, G. Fink, T. Henriksen, G. Ebersbach, Z. Pirtošek, V. Visser-Vandewalle, A. Antonini, L. Timmermann, K. Ray Chaudhuri   +23 more
semanticscholar   +1 more source

A Wearable Sweat Band for Noninvasive Levodopa Monitoring.

Nano letters (Print), 2019
Levodopa is the standard medication clinically prescribed to patients afflicted with Parkinson's disease. In particular, the monitoring and optimization of levodopa dosage is critical to mitigate the onset of undesired fluctuations in the patients ...
Li-Chia Tai, T. S. Liaw, Yuanjing Lin, H. Nyein, Mallika Bariya, Wenbo Ji, M. Hettick, Chunsong Zhao, Jiangqi Zhao, Lei Hou, Zhen Yuan, Z. Fan, A. Javey   +12 more
semanticscholar   +1 more source

Application of Mathematical Models in Drug Release Kinetics of Carbidopa and Levodopa ER Tablets

, 2017
The aim of present work is to determine and analyse the kinetics of drug release from the matrix tablet by employing various mathematical models. A study was done with Carbidopa and Levodopa ER tablets, 50 mg/200 mg by employing wet granulation technique
H. Baishya
semanticscholar   +1 more source

Levodopa and the progression of Parkinson's disease.

New England Journal of Medicine, 2004
BACKGROUND Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's
S. Fahn, D. Oakes, I. Shoulson, K. Kieburtz, A. Rudolph, A. Lang, C. Olanow, C. Tanner, K. Marek   +8 more
semanticscholar   +1 more source

Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases

Frontiers in Neurology, 2023
BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki, Yayoi Kawata, Ayako Hayashi, Masaki Arai, Shinji Fujimoto   +4 more
doaj   +1 more source

Levodopa-induced pseudopheochromocytoma

European Journal of Case Reports in Internal Medicine, 2023
Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso, Ana Silveira, Sara Duarte, Ruth Fortes, Ahmed Botelho, Ana Simas, Rui Suzano   +6 more
openaire   +3 more sources

Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts

Annals of Neurology, 2018
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal ...
A. Espay, F. Morgante, A. Merola, A. Fasano, L. Marsili, Susan H. Fox, E. Bézard, B. Picconi, P. Calabresi, Anthony E. Lang   +9 more
semanticscholar   +1 more source

Electrostimulation of Brain Deep Structures in Parkinson's Disease [PDF]

arXiv, 2021
The study involved 56 patients with advanced and late stages of Parkinsons disease, which could be considered as potentially requiring neurosurgical treatment-electrical stimulation of deep brain structures. An algorithm has been developed for selecting patients with advanced and late stages of Parkinsons disease for neurological treatment-implantation
arxiv  

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

New England Journal of Medicine, 2000
BACKGROUND There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist. METHODS In this prospective, randomized, double-blind study, we compared the safety and efficacy of the ...
O. Rascol, D. Brooks, A. Korczyn, D. Pp, C. Clarke, A. Lang   +5 more
semanticscholar   +1 more source

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

JAMA Neurology, 2017
Importance Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge.
A. Schapira, S. Fox, R. Hauser, J. Jankovic, W. Jost, C. Kenney, J. Kulisevsky, R. Pahwa, W. Poewe, R. Anand   +9 more
semanticscholar   +1 more source